GlucoTrack(GCTK) - 2025 Q4 - Annual Results

Exhibit 99.1 Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Of ice (USPTO) issued patents for Glucotrack's implantable continuous blood glucose monitoring (CBGM) technology, strengthening the Company's intellectual property portfolio Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) — ...